Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization

CMAJ. Canadian Medical Association Journal

Volumn 166, Issue 6, 2002, Pages 737-745

  Schneeweiss, Sebastian ^a   Soumerai, Stephen B ^a   Glynn, Robert J ^a   Maclure, Malcolm ^a   Dormuth, Colin ^a   Walker, Alexander M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; QUINAPRIL; RAMIPRIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; COST CONTROL; DIABETES MELLITUS; DRUG COST; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRESCRIPTION; SOCIOECONOMICS;

EID: 0036207932     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. The American health care system. Expenditures
2. National health expenditures in 1997: More slow growth
3. Pharmaceutical cost containment and innovation in the United States
4. A population-wide profile of prescription drug use in Saskatchewan, 1989
5. The Medicare prescription drug benefit: How will the game be played?
6. On the evaluation of drug benefits policy changes with longitudinal claims data: The policy maker's versus the clinician's perspective
7. Reference-based pricing of prescription drugs: Exploring the equivalence of angiotensin-converting-enzyme inhibitors
8. A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada
9. Reference-based pricing of prescription drugs
10. Reference-based pricing in British Columbia: Implications for cardiologists - An analysis
11. Coverage of drug costs: Reference-based pricing
12. The Canadian Cardiovascular Society and reference-based drug pricing
13. Copayments for ambulatory care: Penny-wise and pound-foolish
14. The effect of a Medicaid drug copayment program on the utilization and cost of prescription services
15. Payment restrictions for prescription drugs in Medicaid: Effects on therapy, cost, and equity
16. The differential impact of copayment on drug use in a Medicaid population
17. Adverse events associated with prescription drug cost-sharing among poor and elderly persons
18. 1999 Canadian recommendations for the management of hypertension
19. The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate hypertension: A multicenter study
20. Lisinopril and nifedipine in essential hypertension: A Norwegian multicenter study on efficacy, tolerability and quality-of-life in 828 patients
21. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
22. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure
23. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction
24. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
25. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials
26. Left ventricular remodeling after acute myocardial infarction
27. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
28. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
29. Adherence to pharmacologic management of hypertension
30. Ensuring cost-effective drug strategies
31. Trends and determinants of prescription drug expenditures in the elderly: Data from the British Columbia Pharmacare Program
32. Agreement between physicians' office records and Medicare Part B claims data
33. Bias in the coding of hospital discharge data and its implications for quality assessment
34. Agreement between drug treatment data and a discharge diagnosis of diabetes mellitus in the elderly
35. The accuracy of Medicare's hospital claims data: Progress has been made but problems remain
36. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes
37. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia
38. Nordic drug index: Defined daily doses
39. Analysis of interrupted time series mortality trends: An example to evaluate regionalized perinatal care
40. Trend analysis
41. Autocorrelated disturbances
42. A chronic disease score from automated pharmacy data
43. Replicating the chronic disease score (CDS) from automated pharmacy data
44. What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?
45. Reference-based pricing (RBP) of prescription drugs
46. Thrombotic vascular events after change of statin
47. A critical analysis of studies of state drug reimbursement policies. Research in need of discipline
48. Influences of educational interventions and adverse news about calcium-channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia
49. Withdrawing payment for nonscientific drug therapy
50. Compliance with antihypertensive therapy among elderly Medicaid enrollees: The role of age, gender, and race
51. Psychosocial factors influence control of moderate and severe hypertension